Main objectives:
# Improvement of regulatory framework in the field of intellectual property in order to extend the access to HIV and Hepatitis C treatment
# Improved conditions for the presence in the market of competing organizations supplying life-saving drugs for treatment of HIV and Hepatitis C.
# Conditions created for the introduction of the most effective treatment regimens for HIV and Hepatitis C recommended by WHO through the revision of the clinical protocol for the treatment of HIV and Hepatitis C, revision of the list of drugs for HIV treatment.
# Improved conditions of drugs registration for manufacturers of generics for the treatment of HIV and Hepatitis C with the same quality and safety.
# Extended state financing of HIV treatment.
# Expanded participation of communities of PLHIV and people living with Hepatitis C in the advocacy activity aimed at the extension of access to HIV and Hepatitis C treatment, reducing prices for the drugs and alteration of legislation related to intellectual property

In 2012, the Coalition for access to drugs was created, with the Partnership Network Association as one of its memebers. In the previous years, the Association has done significant work to change intellectual property legislation. The association worked on the Patent Law that includes the use of TRIPS flexibilities, which in spring 2014 was registered in the Parliament of the country.

The Kyrgyz Republic is among seven countries with the highest rates of new HIV infections, and the total number of HCV-infected exceeds 5% of the country population. Both HCV and HIV epidemics grow faster than treatment accessibility is provided. Against this background, the current patent legislation, lack of anti-monopoly legislation and imperfect system of drugs registration reduce the competitive opportunities among pharmaceutical companies, resulting in high medicine prices.